ARTICLE | Company News
Eureka Therapeutics, Novartis, Memorial Sloan Kettering deal
February 3, 2014 8:00 AM UTC
Eureka and Memorial Sloan Kettering Cancer Center granted Novartis exclusive, worldwide rights to develop and commercialize ESK1, a preclinical mAb against Wilm's Tumor 1 ( WT1) in development for ca...